Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 4
2011 2
2012 15
2013 22
2014 10
2015 10
2016 9
2017 11
2018 6
2019 1
2020 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24574334

79 results

Results by year

Filters applied: . Clear all
Page 1
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Cardin DB, et al. Cancer Med. 2014 Jun;3(3):572-9. doi: 10.1002/cam4.208. Epub 2014 Feb 12. Cancer Med. 2014. PMID: 24574334 Free PMC article. Clinical Trial.
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV. Buttigliero C, et al. Oncologist. 2019 Jun;24(6):e251-e259. doi: 10.1634/theoncologist.2018-0089. Epub 2018 Aug 23. Oncologist. 2019. PMID: 30139835 Free PMC article. Clinical Trial.
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. Zhu AX, et al. J Clin Oncol. 2015 Feb 20;33(6):559-66. doi: 10.1200/JCO.2013.53.7746. Epub 2014 Dec 29. J Clin Oncol. 2015. PMID: 25547503 Free article. Clinical Trial.
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A. Thomas MB, et al. Oncology. 2018;94(6):329-339. doi: 10.1159/000485384. Epub 2018 May 2. Oncology. 2018. PMID: 29719302 Free PMC article. Clinical Trial.
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF. Lind JS, et al. Clin Cancer Res. 2010 Jun 1;16(11):3078-87. doi: 10.1158/1078-0432.CCR-09-3033. Epub 2010 Apr 15. Clin Cancer Res. 2010. PMID: 20395213 Free article. Clinical Trial.
79 results